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ABSTRACT
Osteoporosis is characterized mainly by low bone mineral density (BMD). Many cytokines and chemokines have been related with bone
metabolism. Monocytes in the immune system are important sources of cytokines and chemokines for bone metabolism. However, no
study has investigated in vivo expression of a large number of various factors simultaneously in human monocytes underlying
osteoporosis. This study explored the in vivo expression pattern of general cytokines, chemokines, and their receptor genes in human
monocytes and validated the significant genes by qRT-PCR and genetic association analyses. Expression profilings were performed in
monocyte samples from 26 Chinese and 20 Caucasian premenopausal women with discordant BMD. Genome-wide association analysis
withBMD variationwasconducted in1000unrelated Caucasians. Weselected168 cytokines, chemokines,osteoclast-related factors, and
theirreceptor genes for analyses. Significantly, the signal transducer and activator oftranscription 1(STAT1)gene was upregulated in the
low versus the high BMD groups in both Chinese and Caucasians. We also revealed a significant association of the STAT1 gene with BMD
variation in the 1000 Caucasians. Thus we conclude that the STAT1 gene is important in human circulating monocytes in the etiology of
osteoporosis.  2010 American Society for Bone and Mineral Research.
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Introduction
O
steoporosis is mainly characterized by low bone mineral
density (BMD). Genetic factors have important influences
on BMD and osteoporosis.
(1–3) Recent studies have shown that
the immune system is strongly related to bone metabolism in
terms of osteoimmunology.
(4–8) Pathologic bone resorption was
observed in immune system–related diseases such as auto-
immune arthritis, periodontitis, Paget’s disease, and bone
tumors.
(9)
Monocytes,important cellsinimmunesystem, produceawide
variety of factors such as interleukin 1 (IL-1), IL-6, tumor necrosis
factor (TNF), transforming growth fator beta (TGF-b), and
1,25-dihydroxyvitamin D3 [1,25(OH)2D3].
(10) These factors are
involved in bone metabolism by regulating osteoclastic
differentiation. Monocytes are also potential precursors of
osteoclasts.
(11,12) In vitro studies demonstrated that monocytes
can differentiate into osteoclasts with bone resorption
function.
(13,14)
However, it is unknown whether other factors and mechan-
isms to regulate these factors are important in the ability of
monocytes to affect bone metabolism. To address these
questions, scientists have screened the differential gene
expressions in osteoclastogenic cells using a high-throughput
microarray platform.
(15,16) Microarray technology has been used
successfully for detection of gene expression profiles in diseases
such as inflammatory breast cancer and urinary bladder
cancer.
(17,18) Theoretical studies also supported the reliability
of using a microarray platform for the quantitative characteriza-
tion of gene expression.
(19,20) However, differential gene
expression profiles in circulating monocytes associated with
BMD variation had not been investigated until our previous
research in Caucasian females.
(16) In that study, we showed that
chemokine receptor 3 (CCR3), histidine decarboxylase (HDC), and
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339glucocorticoid receptor (GCR) genes in circulating monocytes
potentially contributed to bone metabolism.
(16)
The present study aims to identify significantly differentially
expressed genes from 168 selected cytokine, chemokine, and
osteoclastogenesis-related genes in circulating monocytes
between the high and low BMD groups in Chinese Han females
and validate the significant expression in Caucasian women. We
also performed single-nucleotide polymorphism (SNP) associa-
tion analysis with BMD to find further evidence of the identified
genes at the DNA level.
Materials and Methods
Chinese subjects
The study was approved by the Research Administration
Department of Hunan Normal University. Eight hundred and
seventy-eight females who were Chinese Hans were recruited
from Changsha City. All subjects signed informed-consent
documents before entering the project. Healthy female subjects
aged of 20 to 45 years were included because BMD reaches its
peak and is most stable during this period. For each subject, we
collected information on age, sex, medical history, family history,
menstrual history, smoking history, physical activity, alcohol use,
tea and coffee consumption, diet habits, etc. Female subjects
must have regular menses to avoid the effects of menopause on
BMD. Subjects with chronic diseases and conditions that
potentially may affect bone mass have been excluded from
the study. These diseases/conditions included chronic disorders
involving vital organs (e.g., heart, lung, liver, kidney, and brain),
serious metabolic diseases (e.g., diabetes, hypo- and hyperpar-
athyroidism, and hyperthyroidism, etc.), skeletal diseases (e.g.,
Paget’s disease, osteogenesis imperfecta, and rheumatoid
arthritis, etc.), chronic use of drugs affecting bone metabolism
(e.g., corticosteroid therapy and anticonvulsant drugs), and
malnutrition conditions (e.g., chronic diarrhea, chronic
ulcerative colitis, etc.). From the 100 top and 100 bottom hip
BMD subjects we recruited all who consented to enter
our potential future projects, including 14 high hip BMD
(mean SD¼1.03 0.05g/cm
2) subjects and 12 low hip BMD
(mean SD¼0.7 0.06g/cm
2) subjects (Table 1). Thirty milli-
liters of peripheral blood were drawn for each selected subject.
BMD measurement
BMD (g/cm
2) at the lumbar spine (L1–4, anteroposterior view)
and total hip (femoral neck, trochanter, and intertrochanter
region) was measured by a Hologic 4500-W dual-energy X-ray
absorptiometry (DXA) (Hologic Corp., Waltham, MA, USA). The
DXA scanner was calibrated daily, and long-term precision was
monitoredwithexternalspineandhipphantoms.Thecoefficient
of variation (CV) of measured BMD values was 0.80% at the hip.
Monocyte isolation
A monocyte negative isolation kit (Dynal Biotech, Inc., Lake
Success,NY,USA)wasusedtoisolatecirculatingmonocytesfrom
30mL of whole blood following the procedures recommended
by the manufacturer. The kit contains a mixture of antibodies for
CD2, CD7, CD16, CD19, CD56, and CD235a to deplete T cells, B
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340 Journal of Bone and Mineral Research CHEN ET AL.cells, natural killer cells, erythrocytes, and granulocytes (if
present), leaving monocytes untouched, pure, viable, and free of
the surface-bound antibody and beads. Monocyte purity was
assessed by flow cytometry (BD Biosciences, San Jose, CA, USA)
with fluorescence-labeled antibodies PE-CD14 and FITC-CD45.
The purity was 86% on average (Fig. 1).
Total RNA extraction and microarray procedure
Total RNA from monocytes was extracted using a Qiagen RNeasy
Mini Kit (Qiagen, Inc., Valencia, CA, USA). RNA integrity was
assessed by using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). A total of 10mg RNA from
each sample was converted into biotinylated fragmented cRNA
(BioArray HighYield RNA Transcription Labeling Kit, Enzo
Diagnostics) that was hybridized (Affymetrix Genechip Hybridi-
zation Oven 640) to HG-U133 plus 2.0 GeneChip oligonucleotide
arrays (Affymetrix, Santa Clara, CA, USA), which contains 54,675
sets of oligonucleotide probes that correspond to approximately
38,500 unique human genes, and then washed (Affymetrix
Fluidics Station 450), stained with phycoerythrin-streptavidin,
and scanned using Affymetrix Gene Array Scanner 3000.
Statistical analysis
Transciptome-wide expression profiling involves a large number
of genes and thus incorporates tremendous multiple tests. Some
genes with suggestive significance may be excluded after the
multiple-testing correction. If some genes are tightly related in a
functionally relevant pathway, the P value for any single gene
may not be significant after the multiple-testing correction.
However, a focused expression screen on potential functional
relevant genes largely can reduce the multiple tests and may
increase the statistical power. Considering the multicomparison
problem and the function of monocytes, 168 candidate genes
were selected for statistical analyses. The 168 genes are all
available cytokines, chemokines, osteoclast-related factors, and
their receptors selected for our focused expression analyses of
the Affymetrix HG133 plus 2.0 gene data set (see Appendix
table). Microarray Suite 5.0 (MAS 5.0, Affymetrix) software was
used to generate the array raw data files (CEL files). Then the
probe-level data in CEL files were converted into expression
measures and normalized by the robust multiarray average
algorithm (RMA, www.bioconductor.org).
(21) The differential
expression analysis between low and high BMD samples was
conducted by a nonparameter Wilcoxon signed-rank test. A
Benjamini and Hochberg (BH) stepwise procedure was used for
multiple-comparison adjustment,
(22) and an adjusted P .05 was
used as the significant criterion. Fisher’s exact test was used in
the canonical pathway analysis by Ingenuity Pathways Analysis
(IPA) software (Ingenuity Systems, www.ingenuity.com) to test
the association between genes within a canonical pathway and
BMD variation. According to the similarity of gene expression,
the differentially expressed genes were further analyzed for two-
dimensional hierarchical clustering at both gene and sample
levels.
(23)
Array replication in Caucasians
In this independent microarray study, we recruited 20
premenopausal Caucasian women, 10 with high BMD (spine
or hipZ-scoregreater than þ0.84)and 10 with low BMD (spineor
hip Z-score less than  0.84; see Table 1) from the vicinity of
Creighton University in Omaha, Nebraska, USA, for differential
expression analyses in their circulating monocytes. Although the
weights in the high BMD group were higher than in the low BMD
group, no significant correlation of BMD with weight was
detected in the low or high BMD group. This study was approved
by the Institutional Review Board, and all the subjects signed
informed-consent documents before entering the project. The
inclusion and exclusion criteria were the same as in the Chinese
population, but the age criterion was limited to the narrow
range of 39 to 45 years, within the peak BMD range of 20 to
45 years. For the Caucasian samples, we used the Affymetrix HG-
133A instead of the HG-U133 plus 2.0 that we used for the
Chinese samples (the HG-133A chip contains fewer genes than
the HG-U133 plus 2.0), but all the other experimental procedures
and statistical analyses were the same as we described for
Chinese samples.
Validation by qRT-PCR in Caucasians
We used two-step qRT-PCR to confirm differentially expressed
genes.Reverse-transcriptionreactionswereperformedina50mL
reaction volume containing 5mL1 0   PCR Buffer II, 11mL2 5m M
MgCl2,1 0mL dNTPs, 1.25mL MULV reverse transcriptase, 1.0mL
RNase inhibitor, 2.5mL Oligo d(T), 0.5mg total RNA, and water to
50mL. All these reagents were supplied by Applied Biosystems
(Foster City, CA, USA). Reaction conditions were as follows: 10
minutes at 258C, 30 minutes at 488C, and 5 minutes at 958C. Real-
time quantitative PCR was performed in a 25mL reaction volume
using standard protocols on an Applied Biosystems 7900HT.
Briefly, 2.5mL of cDNA was mixed with 12.5mL of TaqMan
universal PCR master mix (2 ), 1.25mL of TaqMan gene express
assay mix (contains forward and reverse primers and labeled
probe), 1.25mL of human GAPDH probe (20 ), and 7.5mLo f
Fig. 1. Flow cytometer analysis of the percentage of CD14
þ/CD45
þ cells
from human blood. CD14 and CD45 are the specific membrane markers
on monocytes and mononuclear cells, respectively.
STAT1 IN MONOCYTES WITH BMD Journal of Bone and Mineral Research 341water. The thermocycling conditions were as follows: 2 minutes
at 508C, 10 minutes at 958C, and 40 cycles of 15seconds at
95 8C plus 1 minute at 608C. Based on the relative gene
expression 2
 DDCt,
(16) we performed Student’s t test to confirm
the differential expression genes. All reactions were run in
triplicates for each gene.
Confirmation of significant genes in SNP
association study
Subjects and phenotype
For the association study, 1000 unrelated Caucasian subjects
were identified from our established and expanding genetic
repertoire, currently containing more than 6000 subjects. All
subjects were U.S. Caucasians of European origin. The inclusion
and exclusion criteria were the same as in the Chinese
population for expression study, but males and postmenopausal
women were included. The basic characteristics of all subjects
are listed in Table 1. BMD values at spine and hip were measured
using the Hologic 4500A DXA (Hologic, Inc., Bedford, MA, USA).
The coefficient of variation of the DXA measurement was
approximately 1.98% for spine BMD and 1.87% for hip BMD.
Genotyping and statistical analysis
Genomic DNA was extracted from whole human blood using a
commercial isolation kit (GentraSystems, Minneapolis, MN, USA).
Genotyping with the Affymetrix Mapping 250K Nsp and 250K Sty
arrays was performed. Fluorescence intensities were quantified
using an Affymetrix Array Scanner 30007G. Data management
and analyses were performed using the Affymetrix GeneChip
Operating System. The final average Bayesian Robust Linear
Model with Mahalanobis (BRLMM) call rate across the entire
sample reached the high level of 99.14%. We tested the
association of significant genes identified in the expression
studies with BMD in the 1000 Caucasian subjects. Parameters
such as age, age
2, sex, age/age
2-by-sex interaction, height, and
weight were tested for their association with BMD at spine and
hip. The significant (P .05) terms then were included as
covariates to adjustthe raw BMD values for subsequent analyses.
Statistical analyses were performed using genotype and
haplotype association software implemented in PLINK-1.03
(http://pngu.mgh.harvard.edu/purcell/plink/).
(24) Linkage disequi-
librium (LD) patterns were analyzed and plotted with the
correlation coefficient between pairs of loci based on the 1000
unrelated Caucasians using the the Haploview program
(www.broad.mit.edu/mpg/haploview/),
(25) which describes more
or less combinations of alleles. The haplotype block was used to
show chromosome regions with high LD and low haplotype
diversity in haplotpye association studies. MAPPER was used for
searching transcript factor binding sites in the JASPAR database
(http://mapper.chip.org/).
(26)
Results
The basic characteristics of the study subjects are shown in
Table 1. Although hip BMD is the major study phenotype for the
expression analyses in Chinese, spine BMD also was significantly
different between the high and low BMD groups
(P¼1.49 10
 6). There were no significant differences in age
and height traits between the high and low BMD groups forboth
Chinese and Caucasians for expression analyses. However, the
weight and body mass index (BMI, kg/m
2) in the low BMD group
were significantly lower than in the high BMD group in
Caucasians. We performed a general linear regression analyses
for STAT1 expression values and BMD status and incorporated
weight and height as covariates in Caucasians. However, weight
and height are not significant as covariates for STAT1 expression
analysis in the high and low BMD groups (P¼.2529 and .2045,
respectively). This implied that the weight and height in current
study were not confounding factors for BMD in our expression
analyses.
All the nominally significant genes (P<.05) of differential
expression with BMD in Chinese are summarized in Table 2. We
submitted our gene expression profiling to the Gene Expression
Omnibus (www.ncbi.nlm.nih.gov/geo/), and the access number
was GSE7158. After Benjamini and Hochberg correction for
multiple comparisons, the differential expressions of signal
transducer and activator of transcription 1 (STAT1) (adjusted
P¼.02248) and guanylate binding protein 1 (GBP1) (adjusted
P¼.03372) genes were still significant between the low and the
high BMD groups. Expression fold changes of the significant
genes were not large in the present study. The main reason
might be that the female subjects in this study all were 20 to 45
years of age and with regular menses, in contrast with including
both premenopausal and postmenopausal women in our
previous study.
(16) Actually, a 1.5-fold change has been shown
to be significant in other differential gene expression studies.
(27–
30) In addition, BMD is a complex trait, and genes regulating its
variation are not expected to have large differential expressions.
In Fig. 2, a two-dimensional hierarchical dendrogram (based on
the nominally significant genes listed in Table 2) shows the
results of the hierarchical clustering analyses. Low BMD subjects
were mainly clustered to the bottom of the figure.
Many genes in interferon (IFN) pathway were differentially
expressed. STAT1, GBP1, interferon gamma receptor 2 (IFNGR2),
signal transducer and activator of transcription 2 (STAT2),
guanylate binding protein 2 (GPB2), chemokine (C-X-C motif)
ligand 10 (CXCL10), interferon-induced protein 44 (IFI44),
interferon-induced protein 44-like (IFI44L), tumor necrosis factor
(ligand) superfamily member 10 (TNFSF10), interferon-induced
protein 35 (IFI35), and interferon-induced protein with tetra-
tricopeptide repeats 2 (IFIT2) genes had higher expression in the
low BMD group. Furthermore, the canonical pathway analysis
supported the importance of interferon signaling pathway
mediated by the STAT1 gene in determining BMD variation
(P¼1.67 10
 9).
In the interleukin system, interleukin 1 receptor antagonist
(IL1RN) and interleukin 15 (IL15) genes were upregulated in the
low BMD group compared with the high BMD group. However,
IL6 gene expression was not detected.
Interestingly, the differential expression of the STAT1 gene in
circulatingmonocyteswasreplicatedinourongoingcomparison
microarray study between the low and high BMD premenopau-
sal Caucasian women. Consistently, upregulation of the STAT1
gene in the low BMD group also was significant after Benjamini
342 Journal of Bone and Mineral Research CHEN ET AL.and Hochberg correction for multiple testing (P¼.0028,
adjusted P¼.048) (Table 3). qRT-PCR confirmed the significant
differential expression of the STAT1 gene in Caucasians
(P¼.0046) (see Table 3). For the GBP1 gene, we did not find
any significant results in both array and qRT-PCR analyses in
Caucasians.
InSNPgenotypinganalysis usinganadditivemodel,twoSNPs,
rs10199181 (P¼.0028) and rs2030171 (P¼.0264), in the STAT1
gene were associated with spine BMD (Table 4). It was obvious
that subjects with the T allele of rs10199181 possessed high
spine BMD (Fig. 3). Figure 4 shows the correlation coefficient
between pairs of SNPs of the STAT1 gene and reconstructed
haplotype blocks. Interestingly, rs10199181 and rs2030171 were
located in the same block, and a haplotype composed of SNPs
rs16833157-rs2030171-rs10199181 (‘‘G-G-A’’) in the block also
was demonstrated to be significantly associated with spine BMD
(P¼.0029). However, no significant association was detected for
14 SNPs in GBP1 with BMD in Caucasians.
Discussion
In this study we investigated expression of 168 genes related to
cytokines, chemokines, osteoclast formation factors, and
corresponding receptors in monocytes from Chinese Han
women with extremely discordant BMD. Thirteen genes were
found to be differentially expressed. A very interesting
phenomenon was that among the 13 genes, the STAT1, IFI44L,
CXCL10, IFI44, GPB1, and GPB2 genes were expressed in higher
levels in the low BMD group than in the high BMD group, which
Fig. 2. Two-dimensional hierarchical dendrograms clustered both the
rows and columns of the data, the vertical axis showing the clustering of
the subjectswith different BMD(‘‘L’’ for thelow BMDand ‘‘H’’ for thehigh
BMD) and the horizontal axis showing the clustering of the intensity of
different gene expressions.
Table 2. DifferentialExpressionofCytokine,Chemokines,andOsteoclastogenesis-RelatedGenesinBloodMonocytesFromtheLowand
the High BMD Groups in Chinese
Probe ID Gene symbol Gene title
L-BMD
intensity
H-BMD
intensity
Fold
L/H
Raw
P value
Adjusted
P value
200887_s_at STAT1 Signal transducer and activator of
transcription 1
857.21 582.34 1.47 .00008 .02248
 
202269_x_at GBP1 Guanylate binding protein 1 401.11 245.99 1.63 .00024 .03372
 
204533_at CXCL10 Chemokine (C-X-C motif) ligand 10 162.43 83.22 1.95 .00155 .062623
205992_s_at IL15 Interleukin 15 234.54 174.21 1.35 .00310 .096789
214453_s_at IFI44 Interferon-induced protein 44 321.75 186.31 1.73 .00693 .13910
225636_at STAT2 Signal transducer and activator of
transcription 2
404.73 339.6 1.19 .00937 .14628
202688_at TNFSF10 Tumor necrosis factor (ligand)
superfamily member 10
1094.65 889.05 1.23 .01084 .16032
204439_at IFI44L Interferon-induced protein44-like 424.81 153.59 2.77 .01261 .16106
242907_at GBP2 Guanylate binding protein 2 335.3 214.65 1.56 .01677 .18849
209417_s_at IFI35 Interferon-induced protein 35 158.99 115.84 1.37 .02209 .23874
201642_at IFNGR2 Interferon gamma receptor 2 831.32 811.55 1.02 .02882 .27926
212657_s_at IL1RN Interleukin 1 receptor antagonist 468.82 256.04 1.83 .03721 .30425
226757_at IFIT2 Interferon-induced protein with
tetratricopeptide epeats 2
292.64 205.9 1.42 .03721 .30425
Note: Hybridization intensity and ‘‘present’’ status were given based on MAS5 algorithm. L-BMD intensity means hybridization intensity from the low
BMD group; H-BMD intensity means hybridization intensity from the high BMD group. Fold L/H means the ratio of hybridization intensity from the low to
that from the high BMD group. Raw P value means P value before multiple testing corrections. Adjusted P value represents P value adjusted with
Benjamini/Hochberg method, and asterisks
  means significant after Benjamini-Hochberg correction considering 281 probes of selected genes.
STAT1 IN MONOCYTES WITH BMD Journal of Bone and Mineral Research 343is very similar to the IFN-induced gene expression pattern (IFN
pathway). For instance, immature peripheral blood mononuclear
phagocytes stimulated by the type I IFN isoform increased the
expression of 44 genes, including STAT1, IFI44L, CXCL10, IFI44,
GPB1, and GPB2.
(31) Microarray analysis of cells infected with
short hairpin RNA vectors pAB319 and pAB322 showed
enhanced expression of many IFN target genes, such as STAT1,
IFI44L, CXCL10, IFI44, and GPB1.
(32) The increased expression of
IFNpathwaygenesalsowasdetectedinbloodmononuclearcells
from patients with systemic lupus erythematosus and juvenile
dermatomyositis
(33) and in the human fibrosarcoma cell line.
(34)
TheIFNpathwaymayregulateboneresorptionintwoways.First,
interferon-g (IFNG) blocks RANKL-induced osteoclast differentia-
tion.
(9,35) Second, the IFN pathway in circulating monocytes may
stimulatethesecretion ofcytokines IL-1,IL-6,andTNFtoincrease
bone resorption.
(36–38) In this study, the upregulation of STAT1-
Table 3. Microarray and qRT-PCR Results for the Expression of STAT1 Gene in Circulating Monocytes Between the Low and High BMD
Groups in Chinese and in Caucasians
Population Strategy
Expression value in
low BMD
Expression value in
high BMD
Fold change
(L/H) P value
Chinese Affymetrix Microarray HG-U133 Plus 2.0 857.21 292.94 582.34 145.46 1.47 .02248
 
Caucasians Affymetrix Microarray HG-133A 957.18 361.28 575.67 243.00 1.66 .048
 
Caucasians qRT-PCR 3.13 0.84 1.93 0.75 1.62 .0046
Note: Expression value of Affymetrix Microarray was the hybridization intensity based on the MAS5 algorithm; expression value of qRT-PCR was relative
quantity based on 2
 DDCt; fold L/H meansthe ratio of gene expressionfrom the low to that from the highBMD group;
  indicatesthe BH-adjusted P values
for multiple testing.
Table 4. Results for Eight SNP Association Analyses of the STAT1 Gene for Hip and Spine BMD in Caucasians
SNP name SNP ID Position Function Allele
a P HWE
b MAF
c MAF
d
P value
(hip BMD)
P value
(spine BMD)
SNP_A-1830221 rs6718902 191546449 Intron 24 A/G 0.7202 0.237 0.229 .1171 .2828
SNP_A-1966285 rs1914408 191548221 Intron 23 A/G 1 0.235 0.225 .1103 .2447
SNP_A-4228696 rs34997637 191567075 Intron 10 G/A 0.6512 0.234 0.250 .7317 .0895
SNP_A-2224968 rs16833157 191570643 Intron 9 A/G 0.3554 0.056 0.034 .5069 .0672
SNP_A-1966287 rs41379347 191577187 Intron 5 G/A 1 0.008 0.025 N/A N/A
SNP_A-1966288 rs2030171 191577408 Intron 5 A/G 0.6562 0.321 0.300 .5866 .0264
SNP_A-4257270 rs10199181 191581798 Intron 4 T/A 0.7278 0.368 0.342 .2602 .0028
SNP_A-1783099 rs10208033 191587662 5’ near gene G/A 0.6373 0.400 0.450 .8659 .5721
N/A¼The locus was not calculated for the significant test because of minor allele frequency of < 0.05.
aThe former allele represents the minor allele of each locus.
bP value for Hardy-Weinberg equilibrium test.
cMinor allele frequency calculated in our Caucasian sample.
dMinor allele frequency reported for Caucasians in the public database of HapMap CEU.
Fig. 3. BMD (mean SE) in different genotypes of rs10199181 in the
STAT1 gene in Caucasians.
Fig. 4. Pairwiselinkage disequilibrium pattern of eightSNPs in the STAT1
gene in 1000 unrelated Caucasians. Numbers in the squares are 100 by
correlation coefficients (100r
2) between pairs of SNPs. The intensity of
shading is proportional to r
2. SNP IDs in bold represent tag SNPs.
Numbers in parentheses indicate lengths of haplotype blocks.
344 Journal of Bone and Mineral Research CHEN ET AL.mediated IFN pathway genes in the low BMD group suggested
the important effect of STAT1 on bone resorption in vivo in
humans.
For the 13 differentially expressed genes, however, only the
STAT1 and GBP1 genes remained significant after correction for
multipletesting.Inour previousgenome-wide arraystudy onthe
same Chinese samples, we also found significant differential
expression of the STAT1 and GBP1 genes in the array data
analyses aftercorrectingformultiple testing.
(39)However,further
qRT-PCR only confirmed the significance of the GBP1 gene but
not the STAT1 gene.
(39) Thus we tried to replicate significance of
the two genes in our Caucasian expression study on circulating
monocytes from 20 premenopausal Caucasian women (10 with
low BMD and 10 with high BMD) and SNP association study on
1000 unrelated Caucasian subjects. We did not find the
significance of the GPBP1 gene in either replication study.
Interestingly, however, the significance of the STAT1 gene was
found in both replication studies. In particular, significant
upregulation oftheSTAT1genewasfoundinbotharrayandqRT-
PCR experiments in the Caucasian expression study. The STAT1
gene was not differentially expressed in B cells isolated from
peripheral blood between the high and low BMD subjects (data
not shown) who were the same Caucasians for our current
monocyte study. Therefore, it is likely that the alterations in
STAT1 expression only in monocytes, but not in other cells, are
responsible for variations in bone mass in humans.
In the IFN signaling pathway, STAT1 is a critical mediator
gene.
(9,40) In the above-mentioned IFN pathway for regulating
bone resorption, STAT1 mediates the effects of IFNG on both
inhibition of RANKL-induced osteoclast differentiation
(9,35,41) and
secretion of IL-1, IL-6, and TNF.
(36–38) In addition, in dexametha-
sone-treated peripheral blood mononuclear cell (PBMC) cultures,
the inhibited IFNG expression suppressed expression of the
STAT1 gene.
(42) Furthermore, in lupus nephritis patients, basal
expression of STAT1 was significantly higher in monocytes. and
stimulation of the monocyte cultures with IFNG resulted in
phosphorylation of STAT1.
(43)
In mice, the STAT1 gene plays an important role in bone
metabolisminosteoblasts.
(44)Recently,STAT1wasreportedtobe
upregulated in femur tissue in osteoporotic mice,
(45) and this
supports our finding of the high expression of STAT1 in
monocytes in human low BMD groups.
Interestingly, our published linkage study of BMD in 4126
human subjects also identified suggestive univariate and
significant epistatic linkage signals at 2q32, which harbors the
STAT1 gene.
(46) Furthermore, our group recently found sig-
nificantlinkageevidenceon2q32withspineBMDusingbivariate
linkage analysis.
(47) Our current SNP association study also
replicated the significance of the STAT1 gene for spine BMD in
Caucasian samples. No SNP in the STAT1 gene was associated
with hip BMD at the SNP level, perhaps owing to different
genetic determinants for spine BMD and hip BMD traits because
many studies have shown different heritability and genetic loci
underlying the two traits.
(47,48) Hence our results tend to reveal
the significance of STAT1 on spine BMD. Subjects with the T allele
of SNP rs10199181 in the STAT1 gene tended to have a higher
spine BMD than those with other alleles (see Fig. 3). According to
the transcript factor Jaspar database, the T allele of rs10199181 is
likely to bind transcript factor E4BP4, which might be induced by
parathyroid hormone (PTH), a well-know hormone for bone
growth, in osteoblasts.
(49,50) The inducible effect of E4BP4
suggests a negative regulation by glucocorticoids that might
decrease BMD.
(51) Thus it implies that the T allele of rs10199181
in the STAT1 gene may be involved in bone growth metabolism.
Fig. 5. Diagram of the osteoclastogenesis mechanism. The novel pathway mediated by STAT1 in blood monocytes was connected by big hollow arrows.
The solid arrows indicate activation, and the dashed arrows indicate inhibition.
STAT1 IN MONOCYTES WITH BMD Journal of Bone and Mineral Research 345Based on the present results and previous knowledge, we
developed a novel mechanism for osteoclastogenesis (Fig. 5). In
peripheral blood, IFN mediated by STAT1 may stimulate
circulating monocytes to produce cytokines such as IL-1, TNF,
CXCL10, and IL-15 that increase the bone resorption function of
osteoclasts. Another pathway in the bone microenvironment
also may be triggered by upregulated STAT1 and IFN, which may
inhibit osteoblatogenesis. In this study, no expression of the
RANK and TRAF6 genes in circulating monocytes was detected,
suggestingthatosteoclastformationwascompletelyinhibitedin
circulating monocytes. The fact that osteoclast differentiation
was not initiated in peripheral circulating monocytes in both the
high and low BMD groups is possibly because osteoclast
formation from monocytes may occur only in a special
microenvironment.
(52)
Our current research studied and found the importance of
only the STAT1 gene in the function of monocytes or osteoclasts
on bone metabolism, which, however, did not address the
reported importance of the STAT1 gene in osteoblasts.
(9,44)
Insummary,ourresults supportthe factthat theSTAT1genein
circulating monocytes plays important roles in bone metabolism
and also suggests that gene expression of the STAT1-mediated
IFN pathway may be important for osteoporosis.
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Appendix Table
Expression of 168 genes (281 probes) Related to Cytokine, Chemokine, and Osteoclastogenesis-Related Genes in Blood Monocytes From
the Low and High BMD Groups
Probe ID
Gene
symbol Gene title
L-BMD
intensity
H-BMD
intensity
Fold
L/H
Raw
P value
Adjusted
P value
200887_s_at STAT1 Signal transducer and activator of
transcription 1, 91kDa
857.21 582.34 1.47 0.00008 0.02248
 
202269_x_at GBP1 Guanylate binding protein 1,
interferon-inducible, 67kDa,
guanylate binding protein 1,
interferon-inducible, 67kDa
401.11 245.99 1.63 0.00024 0.03372
 
209969_s_at STAT1 Signal transducer and activator of
transcription 1, 91kDa
181.82 99.56 1.83 0.00043 0.04027
 
231577_s_at GBP1 Guanylate binding protein 1,
interferon-inducible, 67kDa
680 363.24 1.87 0.00075 0.052687
207375_s_at IL15RA Interleukin 15 receptor, alpha 94.78 82.73 1.15 0.00156 0.062623
204533_at CXCL10 chemokine (C-X-C motif) ligand 10 162.43 83.22 1.95 0.00155 0.062623
204533_at CXCL10 Chemokine (C-X-C motif) ligand 10 162.43 83.22 1.95 0.00155 0.062623
(Continued)
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Gene
symbol Gene title
L-BMD
intensity
H-BMD
intensity
Fold
L/H
Raw
P value
Adjusted
P value
202270_at GBP1 Guanylate binding protein 1,
interferon-inducible, 67kDa,
guanylate binding protein 1,
interferon-inducible, 67kDa
518.93 288 1.8 0.00221 0.077626
205992_s_at IL15 Interleukin 15 234.54 174.21 1.35 0.0031 0.096789
216598_s_at CCL2 Chemokine (C-C motif) ligand 2 16.08 8.82 1.82 0.00396 0.11128
222484_s_at CXCL14 Chemokine (C-X-C motif) ligand 14 2.68 3.6 0.75 0.00503 0.12849
217371_s_at IL15 Interleukin 15 114.54 88.29 1.3 0.00693 0.1391
214453_s_at IFI44 Interferon-induced protein 44 321.75 186.31 1.73 0.00693 0.1391
1560791_at CXCL9 Chemokine (C-X-C motif) ligand 9 8.51 8.08 1.05 0.00692 0.1391
217502_at IFIT2 Interferon-induced protein with
tetratricopeptide repeats 2
104.43 75.69 1.38 0.00746 0.13975
207902_at IL5RA Interleukin 5 receptor, alpha 22.33 19.24 1.16 0.00861 0.14628
236897_at IL17RB Interleukin 17 receptor, beta 3.45 5.03 0.69 0.00933 0.14628
225636_at STAT2 Signal transducer and activator of
transcription 2, 113kDa
404.73 339.6 1.19 0.00937 0.14628
202688_at TNFSF10 Tumor necrosis factor (ligand)
superfamily, member 10, tumor
necrosis factor (ligand) superfamily,
member 10
1094.65 889.05 1.23 0.01084 0.16032
1560999_a_at IL12RB2 Interleukin 12 receptor, beta 2 7.89 7.96 0.99 0.01247 0.16106
204439_at IFI44L Interferon-induced protein 44-like 424.81 153.59 2.77 0.01261 0.16106
205599_at TRAF1 TNF receptor-associated factor 1 20.8 23.99 0.87 0.01168 0.16106
202748_at GBP2 Guanylate binding protein 2,
interferon-inducible, guanylate
binding protein 2,
interferon-inducible
307.78 240.71 1.28 0.01354 0.16542
227264_at TRAF6 TNF receptor-associated factor 6 31.43 31.59 0.99 0.01545 0.18089
242907_at GBP2 Guanylate binding protein 2,
interferon-inducible
335.3 214.65 1.56 0.01677 0.18849
209417_s_at IFI35 Interferon-induced protein 35 158.99 115.84 1.37 0.02209 0.23874
204747_at IFIT3 Interferon-induced protein with
tetratricopeptide repeats 3
162.68 103.01 1.58 0.0236 0.24561
201642_at IFNGR2 Interferon gamma receptor 2 (interferon
gamma transducer 1)
831.32 811.55 1.02 0.02882 0.27926
214038_at CCL8 Chemokine (C-C motif) ligand 8 34.53 23.4 1.48 0.02868 0.27926
212657_s_at IL1RN Interleukin 1 receptor antagonist 468.82 256.04 1.83 0.03721 0.30425
211517_s_at IL5RA Interleukin 5 receptor, alpha 18.71 19.07 0.98 0.03265 0.30425
204863_s_at IL6ST Interleukin 6 signal transducer (gp130,
oncostatin M receptor)
80.19 57.06 1.41 0.04215 0.30425
206693_at IL7 Interleukin 7 28.73 32.91 0.87 0.03724 0.30425
206618_at IL18R1 Interleukin 18 receptor 1 11.01 21.06 0.52 0.04753 0.30425
221658_s_at IL21R Interleukin 21 receptor 11.34 13.19 0.86 0.03918 0.30425
237493_at IL22RA2 Interleukin 22 receptor, alpha 2 10.52 14.41 0.73 0.04177 0.30425
1552912_a_at IL23R Interleukin 23 receptor 5.7 5.07 1.12 0.04464 0.30425
206569_at IL24 Interleukin 24 16.97 15.76 1.08 0.04745 0.30425
207964_x_at IFNA4 Interferon, alpha 4 15.55 6.72 2.31 0.04468 0.30425
232375_at STAT1 Signal transducer and activator of
transcription 1, 91kDa
142.43 89.1 1.6 0.04764 0.30425
226757_at IFIT2 Interferon-induced protein with
tetratricopeptide repeats 2
292.64 205.9 1.42 0.03721 0.30425
231578_at GBP1 Guanylate binding protein 1,
interferon-inducible, 67kDa
20.83 15.71 1.33 0.04753 0.30425
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P value
210390_s_at CCL14, CCL15 Chemokine (C-C motif) ligand 14,
chemokine (C-C motif) ligand 15
2.8 2.81 0.99 0.04764 0.30425
210549_s_at CCL23 Chemokine (C-C motif) ligand 23 9.67 14.94 0.65 0.03958 0.30425
206172_at IL13RA2 Interleukin 13 receptor, alpha 2 3.4 3.84 0.89 0.05017 0.30837
229263_at IL17RD Interleukin 17 receptor D 6.23 5.42 1.15 0.05048 0.30837
207160_at IL12A Interleukin 12A (natural killer cell
stimulatory factor 1, cytotoxic
lymphocyte maturation factor 1, p35)
4.14 4.3 0.96 0.05355 0.31472
202411_at IFI27 Interferon, alpha-inducible protein 27 32.67 15.61 2.09 0.05376 0.31472
208164_s_at IL9R Interleukin 9 receptor 4.71 5.64 0.84 0.05639 0.32338
208375_at IFNA1 Interferon, alpha 1 2.8 5.44 0.52 0.06403 0.34601
1555464_at IFIH1 Interferon induced with helicase
C domain 1
70.3 50.39 1.4 0.06403 0.34601
1569861_at TRAF5 TNF receptor-associated factor 5 6.6 7.1 0.93 0.06403 0.34601
209687_at CXCL12 Chemokine (C-X-C motif) ligand 12
(stromal cell-derived factor 1)
5.19 6.84 0.76 0.07578 0.40178
224283_x_at IL18BP Interleukin 18 binding protein 15.36 18.89 0.81 0.08023 0.41749
215561_s_at IL1R1 Interleukin 1 receptor, type I 5.66 9.41 0.6 0.08451 0.42486
202687_s_at TNFSF10 Tumor necrosis factor (ligand)
superfamily, member 10, tumor
necrosis factor (ligand) superfamily,
member 10
556.18 440.74 1.26 0.08467 0.42486
234516_at IL1R1 Interleukin 1 receptor, type I 24.23 26.62 0.91 0.09437 0.43578
212196_at IL6ST Interleukin 6 signal transducer (gp130,
oncostatin M receptor)
131.01 127.64 1.03 0.0946 0.43578
206926_s_at IL11 Interleukin 11 11.27 10.34 1.09 0.09268 0.43578
221926_s_at IL17RC Interleukin 17 receptor C 4.33 4.36 0.99 0.09392 0.43578
205476_at CCL20 Chemokine (C-C motif) ligand 20 51.06 9.12 5.6 0.09404 0.43578
210548_at CCL23 Chemokine (C-C motif) ligand 23 3.53 4.61 0.77 0.09949 0.45091
216243_s_at IL1RN Interleukin 1 receptor antagonist 134.21 88.04 1.52 0.10519 0.46185
209827_s_at IL16 Interleukin 16 (lymphocyte
chemoattractant factor)
198.96 253.61 0.78 0.1049 0.46185
211338_at IFNA2 Interferon, alpha 2 6.31 6.85 0.92 0.1101 0.47597
205099_s_at CCR1 Chemokine (C-C motif) receptor 1 381.92 370.82 1.03 0.11671 0.4969
205207_at IL6 Interleukin 6 (interferon, beta 2) 33.83 11.29 3 0.12912 0.49729
204773_at IL11RA Interleukin 11 receptor, alpha 35.77 37.85 0.94 0.12892 0.49729
222974_at IL22 Interleukin 22 6.78 5.04 1.35 0.12906 0.49729
220054_at IL23A Interleukin 23, alpha subunit p19 18.45 22.23 0.83 0.1225 0.49729
207113_s_at TNF Tumor necrosis factor 411.29 195.36 2.11 0.12276 0.49729
208075_s_at CCL7 Chemokine (C-C motif) ligand 7,
chemokine (C-C motif) ligand 7
5.28 8.89 0.59 0.12892 0.49729
1569203_at CXCL2 Chemokine (C-X-C motif) ligand 2 36.79 18.62 1.98 0.12919 0.49729
207681_at CXCR3 Chemokine (C-X-C motif) receptor 3 34.98 46.84 0.75 0.13547 0.51442
39402_at IL1B Interleukin 1, beta 1285.79 443.95 2.9 0.14268 0.52501
207906_at IL3 Interleukin 3 (colony-stimulating factor,
multiple)
2.26 2.21 1.02 0.14947 0.52501
208193_at IL9 Interleukin 9 3.69 3.14 1.17 0.14905 0.52501
206924_at IL11 Interleukin 11 2.88 3.68 0.78 0.14919 0.52501
235531_at IL17RB Interleukin 17 receptor B 20.83 20.61 1.01 0.14234 0.52501
214458_at TRAF3IP1 TNF receptor-associated factor 3
interacting protein 1
11.98 11.86 1.01 0.14878 0.52501
64440_at IL17RC Interleukin 17 receptor C 79.17 86.92 0.91 0.15723 0.52597
229450_at IFIT3 Interferon-induced protein with
tetratricopeptide repeats 3
476.16 293.63 1.62 0.15723 0.52597
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209774_x_at CXCL2 Chemokine (C-X-C motif) ligand 2 601.98 172.21 3.5 0.15723 0.52597
207850_at CXCL3 Chemokine (C-X-C motif) ligand 3 201.37 80.34 2.51 0.15723 0.52597
202948_at IL1R1 Interleukin 1 receptor, type I 31.23 37.41 0.83 0.16448 0.53815
212659_s_at IL1RN Interleukin 1 receptor antagonist 129.83 117.41 1.11 0.1647 0.53815
211372_s_at IL1R2 Interleukin 1 receptor, type II 15.5 19.1 0.81 0.17281 0.54583
1552915_at IL28A Interleukin 28A (interferon, lambda 2) 21.28 18.3 1.16 0.17288 0.54583
223710_at CCL26 Chemokine (C-C motif) ligand 26 19.21 17.31 1.11 0.17244 0.54583
205926_at IL27RA Interleukin 27 receptor, alpha 142.43 145.56 0.98 0.18105 0.55907
204932_at TNFRSF11B Tumor necrosis factor receptor
superfamily, member 11b,
osteoprotegerin (OGP)
10.14 12.21 0.83 0.18001 0.55907
220971_at IL17E Interleukin 17E 10.42 12.41 0.84 0.18921 0.56675
219255_x_at IL17RB Interleukin 17 receptor B 6.93 8.36 0.83 0.18853 0.56675
217199_s_at STAT2 Signal transducer and activator of
transcription 2, 113kDa
31.51 25.83 1.22 0.18959 0.56675
210118_s_at IL1A Interleukin 1, alpha 23.56 10.89 2.16 0.21594 0.57929
211516_at IL5RA Interleukin 5 receptor, alpha 5.92 8.51 0.69 0.21515 0.57929
202859_x_at IL8 Interleukin 8 1850.81 730.41 2.53 0.22677 0.57929
209828_s_at IL16 Interleukin 16 (lymphocyte
chemoattractant factor)
23.08 34.55 0.67 0.2267 0.57929
208402_at IL17 Interleukin 17 (cytotoxic
T-lymphocyte-associated serine
esterase 8)
14.02 19.57 0.72 0.2059 0.57929
221165_s_at IL22 Interleukin 22 21.89 23.56 0.93 0.22486 0.57929
221111_at IL26 Interleukin 26 4.13 5.1 0.81 0.19841 0.57929
225669_at IFNAR1 Interferon (alpha, beta, and omega)
receptor 1
37.99 40.96 0.93 0.22677 0.57929
1552611_a_at JAK1 Januskinase1(aproteintyrosinekinase) 169.58 162.82 1.04 0.22677 0.57929
201422_at IFI30 Interferon, gamma-inducible protein 30 3459.22 3226.64 1.07 0.22646 0.57929
204352_at TRAF5 TNF receptor-associated factor 5 23.86 37.43 0.64 0.20762 0.57929
207900_at CCL17 Chemokine (C-C motif) ligand 17 20.27 20.66 0.98 0.22662 0.57929
207445_s_at CCR9 Chemokine (C-C motif) receptor 9 18.78 21.37 0.88 0.21657 0.57929
205242_at CXCL13 Chemokine (C-X-C motif) ligand 13
(B-cell chemoattractant)
2.43 3.62 0.67 0.1978 0.57929
211469_s_at CXCR6 Chemokine (C-X-C motif) receptor 6 4.67 6.83 0.68 0.21586 0.57929
203687_at CX3CL1 Chemokine (C-X3-C motif) ligand 1 4.28 5.34 0.8 0.20715 0.57929
218002_s_at CXCL14 Chemokine (C-X-C motif) ligand 14 2.03 2.11 0.96 0.23609 0.59767
205067_at IL1B Interleukin 1, beta 1436.05 513.56 2.8 0.25774 0.62978
210744_s_at IL5RA Interleukin 5 receptor, alpha 7.31 10.81 0.68 0.25733 0.62978
1552609_s_at IL28A /// IL28B Interleukin 28A (interferon, lambda 2),
interleukin 28B (interferon, lambda 3)
10.3 10.99 0.94 0.25766 0.62978
242473_at TRAF4 TNF receptor-associated factor 4 8.1 10.37 0.78 0.25774 0.62978
243977_at IL6 Interleukin 6 (interferon, beta 2) 20.98 24.02 0.87 0.26814 0.64011
204103_at CCL4 Chemokine (C-C motif) ligand 4 828.94 274.36 3.02 0.2688 0.64011
32128_at CCL18 Chemokine (C-C motif) ligand 18
(pulmonary and activation-regulated)
13.14 15.52 0.85 0.26863 0.64011
207433_at IL10 Interleukin 10 6.19 7.02 0.88 0.29161 0.67187
212203_x_at IFITM3 Interferon induced transmembrane
protein 3 (1-8U)
1196.83 954.47 1.25 0.2917 0.67187
211153_s_at TNFSF11 Tumor necrosis factor (ligand)
superfamily, member 11, activator of
NF-kB ligand (RANKL)
4.88 4.41 1.11 0.29137 0.67187
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207794_at CCR2 Chemokine (C-C motif) receptor 2,
chemokine (C-C motif) receptor 2
224.96 310.1 0.73 0.2917 0.67187
216244_at IL1RN Interleukin 1 receptor antagonist 4.14 3.79 1.09 0.31554 0.67755
220056_at IL22RA1 Interleukin 22 receptor, alpha 1 25.21 21.24 1.19 0.30247 0.67755
208173_at IFNB1 Interferon, beta 1, fibroblast 3.43 4.31 0.8 0.31521 0.67755
219209_at IFIH1 Interferon induced with helicase C
domain 1
137.64 113.56 1.21 0.31571 0.67755
221571_at TRAF3 TNF receptor-associated factor 3 36.67 41.08 0.89 0.30354 0.67755
206983_at CCR6 Chemokine (C-C motif) receptor 6 4.79 7.61 0.63 0.31579 0.67755
208059_at CCR8 Chemokine (C-C motif) receptor 8 3.42 3.91 0.87 0.31554 0.67755
204470_at CXCL1 Chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating
activity, alpha)
64.18 28.14 2.28 0.31579 0.67755
206336_at CXCL6 Chemokine (C-X-C motif) ligand 6
(granulocyte chemotactic protein 2)
6.94 9.41 0.74 0.31587 0.67755
207072_at IL18RAP Interleukin 18 receptor accessory
protein
32.1 70.39 0.46 0.32828 0.68858
216020_at IFIH1 Interferon induced with helicase
C domain 1
10.33 7.56 1.36 0.32836 0.68858
207861_at CCL22 Chemokine (C-C motif) ligand 22 3.9 4.21 0.93 0.32728 0.68858
207037_at TNFRSF11A Tumor necrosis factor receptor
superfamily, member 11a, activator of
NF-kB, receptor activator of nuclear
factor kB (RANK)
12.01 13.75 0.87 0.34092 0.69503
205114_s_at CCL3, CCL3L1 Chemokine (C-C motif) ligand 3,
chemokine (C-C motif) ligand 3-like 1
1514.49 513.72 2.95 0.34133 0.69503
221463_at CCL24 Chemokine (C-C motif) ligand 24 4.12 7.67 0.54 0.341 0.69503
208304_at CCR3 Chemokine (C-C motif) receptor 3 55.88 68.99 0.81 0.34133 0.69503
228977_at IL17D Interleukin 17D 3.92 4.04 0.97 0.35405 0.69653
205707_at IL17R Interleukin 17 receptor 296.73 357.67 0.83 0.35446 0.69653
208261_x_at IFNA10 Interferon, alpha 10 12.66 14.89 0.85 0.35446 0.69653
208448_x_at IFNA16 Interferon, alpha 16 20 19.59 1.02 0.35413 0.69653
1562296_at CXCL14 Chemokine (C-X-C motif) ligand 14 10.64 7.69 1.38 0.35446 0.69653
211506_s_at IL8 Interleukin 8 1343.34 417.69 3.22 0.36807 0.69884
1552584_at IL12RB1 Interleukin 12 receptor, beta 1 81.71 88.5 0.92 0.36807 0.69884
208548_at IFNA6 Interferon, alpha 6 25.55 29.9 0.85 0.36741 0.69884
207354_at CCL16 Chemokine (C-C motif) ligand 16 7.33 8.09 0.91 0.36766 0.69884
204606_at CCL21 Chemokine (C-C motif) ligand 21 13.18 9.83 1.34 0.36774 0.69884
224079_at IL17C Interleukin 17C 35.95 36.44 0.99 0.39534 0.7044
219115_s_at IL20RA Interleukin 20 receptor, alpha 4.77 4.78 1 0.38117 0.7044
219971_at IL21R Interleukin 21 receptor 6.05 8.49 0.71 0.39582 0.7044
208344_x_at IFNA13 Interferon, alpha 13 24.68 14.86 1.66 0.38142 0.7044
203153_at IFIT1 Interferon-induced protein with
tetratricopeptide repeats 1,
interferon-induced protein with
tetratricopeptide repeats 1
199.61 122.27 1.63 0.39607 0.7044
201601_x_at IFITM1 Interferon induced transmembrane
protein 1 (9-27)
371.78 359.83 1.03 0.39607 0.7044
205558_at TRAF6 TNF receptor-associated factor 6 40.12 51.7 0.78 0.38101 0.7044
224027_at CCL28 Chemokine (C-C motif) ligand 28 12.05 12.17 0.99 0.3959 0.7044
203666_at CXCL12 Chemokine (C-X-C motif) ligand 12
(stromal cell-derived factor 1)
47.91 55.58 0.86 0.39558 0.7044
237038_at CXCL14 Chemokine (C-X-C motif) ligand 14 4.89 5.25 0.93 0.38044 0.7044
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205291_at IL2RB Interleukin2receptor, beta,interleukin2
receptor, beta
90.85 134.18 0.68 0.42532 0.7114
206148_at IL3RA Interleukin 3 receptor, alpha
(low affinity)
33.42 29.59 1.13 0.42516 0.7114
211000_s_at IL6ST Interleukin 6 signal transducer
(gp130, oncostatin M receptor)
42.99 41.69 1.03 0.42524 0.7114
212195_at IL6ST Interleukin 6 signal transducer
(gp130, oncostatin M receptor)
333.64 330.73 1.01 0.42532 0.7114
207901_at IL12B Interleukin 12B (natural killer cell
stimulatory factor 2, cytotoxic
lymphocyte maturation factor 2, p40)
13.58 15.13 0.9 0.41006 0.7114
1552610_a_at JAK1 Januskinase1(aproteintyrosinekinase) 195.54 234.77 0.83 0.42524 0.7114
238494_at TRAF3IP1 TNF receptor-associated factor 3
interacting protein 1
42.08 48.73 0.86 0.42436 0.7114
206988_at CCL25 Chemokine (C-C motif) ligand 25 9.38 9.41 1 0.42468 0.7114
224240_s_at CCL28 Chemokine (C-C motif) ligand 28 23.78 30.34 0.78 0.425 0.7114
1568934_at CX3CR1 Chemokine (C-X3-C motif) receptor 1 25.24 37.66 0.67 0.425 0.7114
201887_at IL13RA1 Interleukin 13 receptor, alpha 1 267.86 291.22 0.92 0.45571 0.72771
1561853_a_at IL23R Interleukin 23 receptor 4.61 4.55 1.01 0.45463 0.72771
242903_at IFNGR1 Interferon gamma receptor 1 265.56 251 1.06 0.45579 0.72771
214022_s_at IFITM1 Interferon induced transmembrane
protein 1 (9-27)
593.06 624.52 0.95 0.45579 0.72771
208315_x_at TRAF3 TNF receptor-associated factor 3 66.38 70.17 0.95 0.4554 0.72771
206978_at CCR2 Chemokine (C-C motif) receptor 2,
chemokine (C-C motif) receptor 2
556.27 705.5 0.79 0.45579 0.72771
207852_at CXCL5 Chemokine (C-X-C motif) ligand 5 12.5 16.09 0.78 0.45571 0.72771
206974_at CXCR6 Chemokine (C-X-C motif) receptor 6 10.88 15.49 0.7 0.4554 0.72771
217119_s_at CXCR3 Chemokine (C-X-C motif) receptor 3 10.84 21.84 0.5 0.4711 0.7479
211405_x_at IFNA17 Interferon, alpha 17 33.16 36.39 0.91 0.48701 0.76882
217489_s_at IL6R Interleukin 6 receptor 35.97 45.58 0.79 0.52027 0.7818
214950_at IL9R Interleukin 9 receptor 10.43 21.45 0.49 0.5197 0.7818
201888_s_at IL13RA1 Interleukin 13 receptor, alpha 1 107.98 114.14 0.95 0.5202 0.7818
219323_s_at IL18BP Interleukin 18 binding protein 11.17 18.06 0.62 0.52006 0.7818
1552995_at IL27 Interleukin 27 7.78 5.66 1.38 0.50336 0.7818
244261_at IL28RA Interleukin 28 receptor, alpha
(interferon, lambda receptor)
11.39 17.45 0.65 0.52027 0.7818
210643_at TNFSF11 Tumor necrosis factor (ligand)
superfamily, member 11, activator of
NF-kB ligand (RANKL)
7.75 11.01 0.7 0.51998 0.7818
206991_s_at CCR5 Chemokine (C-C motif) receptor 5 53.27 98.45 0.54 0.5202 0.7818
205898_at CX3CR1 Chemokine (C-X3-C motif) receptor 1 1343.17 1679.71 0.8 0.52027 0.7818
220273_at IL17B Interleukin 17B 3.01 6.06 0.5 0.53668 0.79372
224071_at IL20 Interleukin 20 22.93 24.02 0.95 0.53605 0.79372
1555499_a_at IL28RA Interleukin 28 receptor, alpha
(interferon, lambda receptor)
23.78 22.54 1.06 0.53668 0.79372
207538_at IL4 Interleukin 4 9.75 10.11 0.96 0.55412 0.80688
204912_at IL10RA Interleukin 10 receptor, alpha 681.13 656.72 1.04 0.55419 0.80688
223030_at TRAF7 TNF receptor-associated factor 7 13.44 18.42 0.73 0.55405 0.80688
205403_at IL1R2 Interleukin 1 receptor, type II 36.25 48.67 0.74 0.58915 0.81153
234967_at IL6ST Interleukin 6 signal transducer (gp130,
oncostatin M receptor)
3.65 3.37 1.08 0.58864 0.81153
1552646_at IL11RA Interleukin 11 receptor, alpha 46.73 58.54 0.8 0.56956 0.81153
222062_at IL27RA Interleukin 27 receptor, alpha 141.68 184.7 0.77 0.58915 0.81153
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204191_at IFNAR1 Interferon (alpha, beta, and omega)
receptor 1
28.97 25.98 1.12 0.58639 0.81153
206332_s_at IFI16 Interferon, gamma-inducible protein 16 742.15 756.26 0.98 0.58915 0.81153
211899_s_at TRAF4 TNF receptor-associated factor 4 8.43 9.49 0.89 0.57062 0.81153
223029_s_at TRAF7 TNF receptor-associated factor 7 39.65 31.97 1.24 0.57141 0.81153
210072_at CCL19 Chemokine (C-C motif) ligand 19 20.58 19.63 1.05 0.58896 0.81153
207955_at CCL27 Chemokine (C-C motif) ligand 27 29.49 33.85 0.87 0.5889 0.81153
211122_s_at CXCL11 Chemokine (C-X-C motif) ligand 11 17.69 8.56 2.07 0.57121 0.81153
205098_at CCR1 Chemokine (C-C motif) receptor 1 514.24 489.35 1.05 0.60695 0.83197
204116_at IL2RG Interleukin 2 receptor, gamma (severe
combined immunodeficiency)
193.16 255.56 0.76 0.62505 0.83249
205945_at IL6R Interleukin 6 receptor, interleukin 6
receptor
258.64 261.18 0.99 0.62505 0.83249
205798_at IL7R Interleukin 7 receptor, interleukin 7
receptor
64.86 104.79 0.62 0.62511 0.83249
206295_at IL18 Interleukin 18 (interferon-g-inducing
factor)
67.16 76.06 0.88 0.62511 0.83249
208965_s_at IFI16 Interferon, gamma-inducible protein 16 347.81 327.78 1.06 0.62511 0.83249
1555759_a_at CCL5 Chemokine (C-C motif) ligand 5 972.23 900.04 1.08 0.62511 0.83249
204864_s_at IL6ST Interleukin 6 signal transducer (gp130,
oncostatin M receptor)
29.53 30.2 0.98 0.66186 0.84938
221947_at IL17RC Interleukin 17 receptor C 47.88 44.71 1.07 0.66175 0.84938
217702_at IL27RA Interleukin 27 receptor, alpha 14.93 12.41 1.2 0.64337 0.84938
214569_at IFNA5 Interferon, alpha 5 6.93 6.7 1.03 0.66083 0.84938
1553574_at IFNE1 Interferon epsilon 1 15.13 14.11 1.07 0.66099 0.84938
201648_at JAK1 Januskinase1(aprotein tyrosinekinase) 543.47 603.1 0.9 0.66197 0.84938
204413_at TRAF2 TNF receptor-associated factor 2 3.8 4.76 0.8 0.6617 0.84938
214974_x_at CXCL5 Chemokine (C-X-C motif) ligand 5 529.1 524.14 1.01 0.66197 0.84938
207849_at IL2 Interleukin 2 6.56 6.19 1.06 0.68047 0.85388
208259_x_at IFNA7 Interferon, alpha 7 26.13 17.84 1.46 0.68057 0.85388
208182_x_at IFNA14 Interferon, alpha 14 27.87 34.38 0.81 0.67964 0.85388
202727_s_at IFNGR1 Interferon gamma receptor 1 1046.25 1094.15 0.96 0.68067 0.85388
210163_at CXCL11 Chemokine (C-X-C motif) ligand 11 17.34 8.8 1.97 0.68041 0.85388
226333_at IL6R Interleukin 6 receptor 370.68 448.76 0.83 0.69968 0.86232
1555016_at IL16 Interleukin 16 (lymphocyte
chemoattractant factor)
37.26 36.32 1.03 0.69914 0.86232
204933_s_at TNFRSF11B Tumor necrosis factor receptor super
family, member 11b, osteoprotegerin
(OGP)
6.46 4.64 1.39 0.69968 0.86232
206337_at CCR7 Chemokine (C-C motif) receptor 7,
chemokine (C-C motif) receptor 7
57.88 65.73 0.88 0.69968 0.86232
207008_at IL8RB Interleukin 8 receptor, beta 179.1 225.48 0.79 0.71877 0.87815
206890_at IL12RB1 Interleukin 12 receptor, beta 1 34.16 45.32 0.75 0.71877 0.87815
206999_at IL12RB2 Interleukin 12 receptor, beta 2 15.38 18.64 0.83 0.73792 0.88263
234408_at IL17F Interleukin 17F 2.32 2.44 0.95 0.73753 0.88263
201315_x_at IFITM2 Interferon induced transmembrane
protein 2 (1-8D)
1306.87 1373.99 0.95 0.73814 0.88263
205392_s_at CCL14, / CCL15 Chemokine (C-C motif) ligand 14,
chemokine (C-C motif) ligand 15
12.36 15.56 0.79 0.73722 0.88263
217028_at CXCR4 Chemokine (C-X-C motif) receptor 4 438.44 468.81 0.94 0.73814 0.88263
211269_s_at IL2RA Interleukin 2 receptor, alpha 24.39 26.68 0.91 0.75738 0.89052
221271_at IL21 Interleukin 21 6.93 7 0.99 0.75726 0.89052
209924_at CCL18 Chemokine (C-C motif) ligand 18
(pulmonary and activation-regulated)
18.18 16.69 1.09 0.75726 0.89052
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203915_at CXCL9 Chemokine (C-X-C motif) ligand 9 42.84 36.42 1.18 0.75742 0.89052
216876_s_at IL17 Interleukin 17 (cytotoxic
T-lymphocyte-associated serine
esterase 8)
2.99 2.74 1.09 0.77715 0.90614
235116_at TRAF1 TNF receptor-associated factor 1 26.19 31.3 0.84 0.7767 0.90614
210133_at CCL11 Chemokine (C-C motif) ligand 11 13.59 17.24 0.79 0.79698 0.92161
208376_at CCR4 Chemokine (C-C motif) receptor 4 21.06 20.58 1.02 0.79671 0.92161
217212_s_at IL9R Interleukin 9 receptor 55.78 61.46 0.91 0.8169 0.92938
214059_at IFI44 Interferon-induced protein 44 67.79 53.63 1.26 0.81693 0.92938
230327_at CCL27 Chemokine (C-C motif) ligand 27 17.48 15.39 1.14 0.81681 0.92938
823_at CX3CL1 Chemokine (C-X3-C motif) ligand 1 21.62 19.67 1.1 0.81681 0.92938
207539_s_at IL4 Interleukin 4 19.68 18.36 1.07 0.85704 0.94123
203233_at IL4R Interleukin 4 receptor 120.73 114.06 1.06 0.85714 0.94123
209575_at IL10RB Interleukin 10 receptor, beta 279.27 295.77 0.94 0.89769 0.94123
211612_s_at IL13RA1 Interleukin 13 receptor, alpha 1,
interleukin 13 receptor, alpha 1
150.14 153.82 0.98 0.89762 0.94123
227401_at IL17D Interleukin 17 receptor D 8.6 7.62 1.13 0.89758 0.94123
224156_x_at IL17RB Interleukin 17 receptor B 18.08 13.81 1.31 0.87718 0.94123
224361_s_at IL17RB Interleukin 17 receptor B 10.48 16.9 0.62 0.89753 0.94123
227997_at IL17RD Interleukin 17 receptor D 27.27 32.84 0.83 0.89762 0.94123
236186_x_at IL17RE Interleukin 17 receptor E 2.38 3.13 0.76 0.85702 0.94123
222868_s_at IL18BP Interleukin 18 binding protein 56.12 58.32 0.96 0.87729 0.94123
222829_s_at IL20RA Interleukin 20 receptor, alpha 4.78 3.86 1.24 0.87731 0.94123
1552917_at IL29 Interleukin 29 (interferon, lambda 1) 33.83 37.22 0.91 0.89769 0.94123
204786_s_at IFNAR2 Interferon (alpha, beta, and omega)
receptor 2
124.38 130.38 0.95 0.89765 0.94123
211676_s_at IFNGR1 Interferon gamma receptor 1, interferon
gamma receptor 1
479.53 517.04 0.93 0.85714 0.94123
205170_at STAT2 Signal transducer and activator of
transcription 2, 113kDa
47.35 46.01 1.03 0.83697 0.94123
208966_x_at IFI16 Interferon, gamma-inducible protein 16 591.69 599.19 0.99 0.85714 0.94123
238846_at TNFRSF11A Tumor necrosis factor receptor
superfamily, member 11a, activator of
NF-kB, receptor activator of nuclear
factor kB (RANK)
18.53 19.76 0.94 0.85694 0.94123
207533_at CCL1 Chemokine (C-C motif) ligand 1 2.38 3.42 0.69 0.8976 0.94123
206407_s_at CCL13 Chemokine (C-C motif) ligand 13 3.59 6.21 0.58 0.83686 0.94123
215101_s_at CXCL5 Chemokine (C-X-C motif) ligand 5 95.13 96.57 0.99 0.89769 0.94123
211919_s_at CXCR4 Chemokine (C-X-C motif) receptor 4,
chemokine (C-X-C motif) receptor 4
318.92 339.41 0.94 0.89767 0.94123
209201_x_at CXCR4 Chemokine (C-X-C motif) receptor 4 305.74 310.98 0.98 0.91805 0.959
210904_s_at IL13RA1 Interleukin 13 receptor, alpha 1 117.07 128.58 0.91 0.9385 0.97313
1405_i_at CCL5 Chemokine (C-C motif) ligand 5 1312.38 1268.12 1.03 0.9385 0.97313
202871_at TRAF4 TNF receptor-associated factor 4 18.68 17.18 1.09 0.95897 0.98707
223454_at CXCL16 Chemokine (C-X-C motif) ligand 16 108.07 104.49 1.03 0.95894 0.98707
207952_at IL5 Interleukin 5 (colony-stimulating factor,
eosinophil)
10.71 13.63 0.79 0.97945 0.99721
207844_at IL13 Interleukin 13 18.97 32.38 0.59 0.97947 0.99721
224514_x_at IL17RC Interleukin 17 receptor C, interleukin 17
receptor C
29.28 36.3 0.81 0.97944 0.99721
206341_at IL2RA Interleukin 2 receptor, alpha 12.05 15.51 0.78 1 1
226218_at IL7R Interleukin 7 receptor 62.02 108.45 0.57 1 1
220745_at IL19 Interleukin 19 25.66 29.86 0.86 1 1
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225661_at IFNAR1 Interferon (alpha, beta, and omega)
receptor 1
76.46 82.39 0.93 1 1
204785_x_at IFNAR2 Interferon (alpha, beta, and omega)
receptor 2
116.43 124.34 0.94 1 1
Note: The data were sorted by adjusted P value. Hybridized intensity and ‘‘present’’ status were given based on the MAS5 algorithm. L-BMD intensity
means average hybridized intensity in the low BMD group; H-BMD intensity means average hybridized intensity in the high BMD group; Fold L/H means
the ration of L-BMD intensity to H-BMD intensity. Raw P value represents P value before multiple testing correction. Adjusted P value represents P value
adjusted with Benjamini/Hochberg method; asterisks indicate significant results after Benjamini-Hochberg correction considering 281 probes of selected
genes.
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